In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Profits lag behind sales growth at Disetronic

This article was originally published in Clinica

Executive Summary

The net income of the Swiss drug delivery company, Disetronic went up by 10% to reach SwFr22 million ($15 million), in the year ended March 31, while total sales increased by 29% to SwFr132 million. The company, of Burgdorf, said that the disproportionately small growth in net income, compared with sales growth, was due to a more conservative investment policy and the currency movements.

You may also be interested in...



COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

'Hunker Down, Expect The Worst And Hope For The Best:' Investment Analyst Advises Medtech Businesses To Cut Costs

Maxim Jacobs, managing partner at Edison Investment Research urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

Topics

UsernamePublicRestriction

Register

MT081620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel